Medical Oncology

, 35:57 | Cite as

Gemcitabine–cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward

  • Vikas Ostwal
  • Rohit Swami
  • Shraddha Patkar
  • Swaratika Majumdar
  • Mahesh Goel
  • Shaesta Mehta
  • Reena Engineer
  • Sarika Mandavkar
  • Suman Kumar
  • Anant Ramaswamy
Original Paper
  • 72 Downloads

Abstract

Data on adjuvant chemotherapy with gemcitabine–cisplatin (GC) in resected gallbladder cancers (GBC) are scarce. Patients who underwent upfront curative resection for GBC from 2010 to 2016 were analyzed. Patients with stage II–III GBC treated with adjuvant GC were analyzed. A total of 242 patients were evaluated, of whom 125 patients received GC regimen as adjuvant chemotherapy. The median age was 50 years (range 31–74), majority were female (77.6%), and 37 patients (29.6%) had raised CA 19.9 levels at baseline. One hundred and thirteen patients (90.4%) underwent radical cholecystectomy with R0 resections. Median number of GC administered was 6, with completion rates of 84%. Toxicity data were comprehensively available for 110 patients, with common grade 3 and grade 4 being neutropenia (9.9%), fatigue (7.3%) and febrile neutropenia (3.6%), respectively. With a median follow-up of 36.88 months, 3-year RFS was 60.3%. Patients with stage II (28%; n = 35), stage IIIA (28%; n = 35) and stage IIIB GBC (44%; n = 55) had a 3-year OS of 91.9, 67 and 58.1% (p = 0.001), respectively. Patients with stage II–III GBC undergoing R0 resections receiving adjuvant GC have good tolerance, high completion rates and encouraging outcomes in a non-trial high GBC prevalence scenario.

Keywords

Gallbladder cancer Adjuvant Gemcitabine–cisplatin 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee as well as with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics committee approval number: IEC/1017/1880/001.

Informed consent

Not applicable as this is a retrospective study of prospective database with no direct contact with the patients. Institutional Ethics committee approved waiver of consent.

Supplementary material

12032_2018_1115_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 kb)

References

  1. 1.
    Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017;109(7):djw324.CrossRefGoogle Scholar
  2. 2.
    Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Ma N, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer. 2015;15:615.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB. 2017;19(9):741–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly J-P, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol [Internet]. 2017; 35(suppl 4S; abstract 225). http://meetinglibrary.asco.org/content/176861-195. Cited 22 Mar 2017.
  6. 6.
    Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(15_suppl):4006.Google Scholar
  7. 7.
    Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, et al. NCCN guidelines insights: hepatobiliary cancers, Version 1.2017. J Natl Compr Cancer Netw. 2017;15(5):563–73.CrossRefGoogle Scholar
  9. 9.
    Kainuma O, Miura F, Furukawa D, Yamamoto H, Cho A, Sano K, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepato-Biliary-Pancreat Sci. 2015;22(11):789–94.CrossRefGoogle Scholar
  10. 10.
    Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer. 2018;11(18):72.CrossRefGoogle Scholar
  11. 11.
    Patkar S, Ostwal V, Ramaswamy A, Engineer R, Chopra S, Shetty N, et al. Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. J Surg Oncol. 2018;117(3):372–9.CrossRefPubMedGoogle Scholar
  12. 12.
    WMA—The World Medical Association. WMA Declaration of Helsinki—Ethical principles for medical research involving human subjects [Internet]. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Cited 25 Jan 2018.
  13. 13.
    Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther. 2006;2(2):52–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28(21):3531–40.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6(17):14744–53.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.CrossRefPubMedGoogle Scholar
  23. 23.
    Wiggers JK, Groot Koerkamp B, Ovadia Z, Busch ORC, Gouma DJ, van Gulik TM. Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection. HPB. 2014;16(7):635–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen H-J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)—a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;31(15):564.CrossRefGoogle Scholar
  25. 25.
    Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB. 2010;12(2):134–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Agrawal S, Lawrence A, Saxena R. Does CA 19-9 have prognostic relevance in gallbladder carcinoma (GBC)? J Gastrointest Cancer. 2017;20:1–6.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Vikas Ostwal
    • 1
  • Rohit Swami
    • 1
  • Shraddha Patkar
    • 2
  • Swaratika Majumdar
    • 1
  • Mahesh Goel
    • 2
  • Shaesta Mehta
    • 3
  • Reena Engineer
    • 4
  • Sarika Mandavkar
    • 1
  • Suman Kumar
    • 5
  • Anant Ramaswamy
    • 1
  1. 1.Department of Medical OncologyTata Memorial HospitalParel, MumbaiIndia
  2. 2.Department of Surgical OncologyTata Memorial HospitalMumbaiIndia
  3. 3.Department of Digestive Diseases and NutritionTata Memorial HospitalMumbaiIndia
  4. 4.Department of Radiation OncologyTata Memorial HospitalMumbaiIndia
  5. 5.Department of RadiologyTata Memorial HospitalMumbaiIndia

Personalised recommendations